# Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain

> **NCT05561023** · PHASE1 · UNKNOWN · sponsor: **Fujian Cancer Hospital** · enrollment: 14 (estimated)

## Conditions studied

- Hawthorn Red Combined Refractory Cancer Pain

## Interventions

- **DRUG:** Hawthorn red pigment

## Key facts

- **NCT ID:** NCT05561023
- **Lead sponsor:** Fujian Cancer Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2023-09-30
- **Final completion:** 2023-09-30
- **Target enrollment:** 14 (ESTIMATED)
- **Last updated:** 2022-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05561023

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05561023, "Phase Ⅰa Clinical Study of Hawthorn Red Pigment Combined With Standard Analgesic for Refractory Cancer Pain". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05561023. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*